The earnings call highlighted significant progress in Revolution Medicines' clinical pipeline and financial strategy, with Breakthrough Therapy designations and robust financial backing. However, increased expenses and net loss, along with uncertain commercialization timelines, present challenges.

Company Guidance -

Q3 2025

During the Revolution Medicines Q2 2025 earnings call, the company provided guidance on several key metrics and strategic priorities. They highlighted their compelling pipeline of three clinical stage RAS(ON) inhibitors—daraxonrasib, elironrasib, and zoldonrasib—and discussed progress in their pancreatic and non-small cell lung cancer programs. Daraxonrasib received Breakthrough Therapy designation from the FDA for previously treated metastatic pancreatic cancer with KRAS G12 mutations, and the RASolute 302 global Phase III trial is expected to complete enrollment this year with a data readout anticipated in 2026. The company also announced a partnership with Royalty Pharma, securing $2 billion in committed capital to support their clinical development and commercialization plans. Revolution Medicines updated their 2025 financial guidance, projecting a full-year GAAP net loss between $1.03 billion and $1.09 billion, reflecting increased R&D and G&A expenses due to global development and commercialization initiatives.

Breakthrough Therapy Designations

Daraxonrasib received Breakthrough Therapy designation from the FDA for previously treated metastatic pancreatic cancer with KRAS G12 mutations. Elironrasib was granted Breakthrough Therapy designation for locally advanced or metastatic KRAS G12C non-small cell lung cancer following prior systemic therapy.

Strong Financial Position

Revolution Medicines reported $2.1 billion in cash and investments, bolstered by a $2 billion partnership with Royalty Pharma, providing flexible capital without equity dilution.

Pipeline Progress

Successful advancement of clinical programs, including daraxonrasib in pancreatic and lung cancers, with multiple trials underway and strategic collaborations enhancing development.

Partnership with Summit Therapeutics

New collaboration to evaluate combinations of Summit's ivonescimab with RevMed's RAS(ON) inhibitors, aiming to enhance therapeutic impact.

Revolution Medicines (RVMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RVMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-1.40 / -	-0.94	―	―	―
Aug 06, 2025	2025 (Q2)	-1.14 / -1.31	-0.81	-61.73% (-0.50)
May 07, 2025	2025 (Q1)	-1.09 / -1.13	-0.7	-61.43% (-0.43)	―
Feb 26, 2025	2024 (Q4)	-0.99 / -1.12	-1.14	1.75% (+0.02)	―
Nov 06, 2024	2024 (Q3)	-0.89 / -0.94	-0.99	5.05% (+0.05)
Aug 07, 2024	2024 (Q2)	-0.78 / -0.81	-0.92	11.96% (+0.11)	―
May 08, 2024	2024 (Q1)	-0.75 / -0.70	-0.72	2.78% (+0.02)	―
Feb 26, 2024	2023 (Q4)	-0.85 / -1.14	-0.63	-80.95% (-0.51)	―
Nov 06, 2023	2023 (Q3)	-1.01 / -0.99	-0.87	-13.79% (-0.12)	―
Aug 08, 2023	2023 (Q2)	-0.82 / -0.92	-0.82	-12.20% (-0.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RVMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$36.67	$34.95	-4.69%
May 07, 2025	$37.66	$41.91	+11.29%
Feb 26, 2025	$40.50	$39.08	-3.51%
Nov 06, 2024	$59.42	$59.10	-0.54%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.